Comparative Pharmacology
Head-to-head clinical analysis: FACTREL versus LUPRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTREL versus LUPRON.
FACTREL vs LUPRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist; stimulates pituitary release of LH and FSH initially, then suppresses gonadotropin secretion after chronic administration due to receptor downregulation.
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary gonadotropin secretion, leading to decreased testosterone and estradiol levels.
100 mcg subcutaneously or 100 mcg intravenously, single dose for pituitary stimulation testing.
3.75 mg intramuscularly once monthly or 11.25 mg intramuscularly once every 3 months. For endometriosis, 3.75 mg intramuscularly monthly for up to 6 months. For central precocious puberty, 0.3 mg/kg intramuscularly every 28 days.
None Documented
None Documented
Terminal elimination half-life is approximately 30-45 minutes. Short half-life necessitates continuous or repeated administration for sustained therapeutic effect.
Terminal half-life approximately 3 hours after subcutaneous administration; in patients with renal impairment, half-life may be prolonged
Primarily renal (95% as unchanged drug and metabolites). Fecal excretion accounts for <5%.
Renal (primarily as metabolites), <5% unchanged; fecal ~5%
Category C
Category C
GnRH Agonist
GnRH Agonist